A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
- PMID: 2498664
- DOI: 10.1038/339394a0
A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin
Abstract
Antibodies and growth factors have been chemically coupled to different toxins to produce cytotoxic molecules that selectively kill cells bearing appropriate antigens or receptors. Antibody-toxin conjugates (immunotoxins) produced using conventional chemical coupling techniques have several undesirable characteristics. The smallest binding unit of an antibody is an Fv fragment which consists of a light and heavy chain variable domain. Recently, active single chain Fv fragments of antibodies have been produced in Escherichia coli by attaching the light and heavy chain variable domains together with a peptide linker. Here we describe the construction and expression in E. coli of a single chain antibody toxin fusion protein, anti-Tac(Fv)-PE40, in which the variable regions of anti-Tac, a monoclonal antibody to the p55 subunit of the human interleukin-2 receptor, are joined in peptide linkage to PE40, a modified form of Pseudomonas exotoxin lacking its binding domain. Anti-Tac(Fv)-PE40 was very cytotoxic to two interleukin-2 receptor-bearing human cell lines but was not cytotoxic to receptor-negative cells.
Similar articles
-
Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells.J Biol Chem. 1990 Sep 5;265(25):15198-202. J Biol Chem. 1990. PMID: 2118522
-
Stabilization of a recombinant Fv fragment by base-loop interconnection and V(H)-V(L) permutation.J Mol Biol. 1997 Apr 25;268(1):107-17. doi: 10.1006/jmbi.1996.0850. J Mol Biol. 1997. PMID: 9149145
-
Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.J Immunol. 1993 Apr 1;150(7):2774-82. J Immunol. 1993. PMID: 8454854
-
Recombinant single-chain immunotoxins against T and B cell leukemias.Leuk Lymphoma. 1994 Mar;13(1-2):1-10. Leuk Lymphoma. 1994. PMID: 8025511 Review.
-
Recombinant immunotoxins for the treatment of Hodgkin's disease (Review).Int J Mol Med. 2000 Nov;6(5):509-14. doi: 10.3892/ijmm.6.5.509. Int J Mol Med. 2000. PMID: 11029515 Review.
Cited by
-
A recombinant, soluble, single-chain class I major histocompatibility complex molecule with biological activity.Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10658-62. doi: 10.1073/pnas.89.22.10658. Proc Natl Acad Sci U S A. 1992. PMID: 1438262 Free PMC article.
-
Systemic immunotoxin therapy of cancer: advances and prospects.Br J Cancer. 1991 Oct;64(4):624-30. doi: 10.1038/bjc.1991.374. Br J Cancer. 1991. PMID: 1911210 Free PMC article. Review. No abstract available.
-
Potent anti-CD5 ricin A chain immunoconjugates from bacterially produced Fab' and F(ab')2.Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):457-61. doi: 10.1073/pnas.90.2.457. Proc Natl Acad Sci U S A. 1993. PMID: 7678457 Free PMC article.
-
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):669-74. doi: 10.1073/pnas.95.2.669. Proc Natl Acad Sci U S A. 1998. PMID: 9435250 Free PMC article.
-
Addressing the Immunogenicity of the Cargo and of the Targeting Antibodies with a Focus on Demmunized Bacterial Toxins and on Antibody-Targeted Human Effector Proteins.Biomedicines. 2017 Jun 2;5(2):28. doi: 10.3390/biomedicines5020028. Biomedicines. 2017. PMID: 28574434 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources